TBPH Earnings Prediction
The chart below shows how TBPH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TBPH sees a -1.40% change in stock price 10 days leading up to the earnings, and a -2.65% change 10 days following the report. On the earnings day itself, the stock moves by +1.25%. This data can give you a slight idea of what to expect for the next quarter's release.
TBPH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
18.75M
6.77%
11.18%
Gross Margin
--
--
--
Operating Margin
-49.06%
38.08%
-10.78%
Net Margin
-82.80%
70.90%
9.99%
EPS
-0.31
-82.35%
19.23%
No Data Available
TBPH Earnings Analysis
Theravance Biopharma Inc Corporation (TBPH.O) Earnings Conference Call
Positive
Record Net Sales Growth: Fourth quarter YUPELRI net sales increased 10% over the fourth quarter of 2023, reaching $66.7 million, an all-time high.
YUPELRI Dose Increase: Hospital performance for YUPELRI was excellent with doses up 49% year-over-year.
CYPRESS Study Enrollment Success: Solid enrollment in the CYPRESS study for ampreloxetine, remaining on track with development timelines.
FDA Interaction and Filing Expectations: Positive exchange with the FDA in December reaffirmed expectations around filing for ampreloxetine should CYPRESS be positive.
Conference Presentations Announcement: Two abstracts accepted for oral presentations at the upcoming American Academy of Neurology meeting in April.
Milestone Payment Achievement: Earned a $50 million milestone payment from Royalty Pharma based on 2024 TRELEGY net sales reported by GSK.
Record Profitability Achievement: YUPELRI recorded its highest level of profitability since launch, with full year sales of $239 million and an 11% growth in demand.
Sales Milestone Potential: Potential for a near-term $25 million sales milestone in the U.S. for YUPELRI, along with future milestones and royalties from China.
TRELEGY Sales Surge: GSK reported full year TRELEGY sales of $3.5 billion, up 26% year-over-year, triggering a $50 million milestone payment to Theravance.
Future Milestone Revenue: Expecting additional $150 million of milestones in the coming 24 months from TRELEGY.
Unmet Need for Ampreloxetine: Ample market research indicates a significant unmet need for ampreloxetine in treating nOH, with 90% of neurologists likely to prescribe it if approved.
Strong Cash Position: Ample cash position with $88 million at year-end, excluding the recent $50 million milestone cash receipt.
Negative
Net Sales Growth Concerns: YUPELRI's net sales growth may not be sustainable due to seasonal dips expected in Q1, which could impact revenue.
Rising Operating Expenses: Operating expenses increased to $22 million in Q4 due to higher commercial and medical affairs spending, which may affect profitability.
Cash Burn Analysis: The company experienced a cash burn of $14 million for the full year, indicating ongoing financial strain despite cash reserves.
Milestone Accounting Changes: The accounting treatment for TRELEGY milestones has changed, meaning only a small portion of future milestones will be recognized as income, potentially affecting reported earnings.
R&D Expense Increase: R&D expenses are expected to increase in the first half of 2025, which could lead to higher losses before improvements are seen in the second half.
TBPH FAQs
How does TBPH typically perform around its earnings report dates?
Is Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TBPH Earning Call Sentiment
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
TBPH.O
0.1%Positive
The earnings call presents a mixed picture: strong YUPELRI sales growth and potential milestone payments are positive, but financial risks and supply chain challenges could dampen enthusiasm. The Q&A section reveals some uncertainty about hospital performance and regulatory timelines, which tempers optimism. Despite the company's commitment to shareholder returns, the lack of clear guidance on certain issues and typical seasonality concerns suggest a cautious market reaction, leading to a neutral sentiment.
